| Issue Date | Title | Author(s) |
| 2023-03-28 | Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies. | Germon, ZP; Sillar, JR; Mannan, A; Duchatel, RJ; Staudt, D; Murray, HC; Findlay, IJ; Jackson, ER; McEwen, HP; Douglas, AM; McLachlan, T; Schjenken, JE; Skerrett-Byrne, DA; Huang, H; Melo-Braga, MN; Plank, MW; Alvaro, F; Chamberlain, J; De Iuliis, G; Aitken, RJ; Nixon, B; Wei, AH; Enjeti, AK; Huang, Y; Lock, RB; Larsen, MR; Lee, H; Vaghjiani, V; Cain, JE; de Bock, CE; Verrills, NM; Dun, MD |
| 2020-12 | Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia. | Dun, MD; Mannan, A; Rigby, CJ; Butler, S; Toop, HD; Beck, D; Connerty, P; Sillar, J; Kahl, RGS; Duchatel, RJ; Germon, Z; Faulkner, S; Chi, M; Skerrett-Byrne, D; Murray, HC; Flanagan, H; Almazi, JG; Hondermarck, H; Nixon, B; De Iuliis, G; Chamberlain, J; Alvaro, F; de Bock, CE; Morris, JC; Enjeti, AK; Verrills, NM |
| 2023-08-30 | Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized, placebo-controlled study by the ALLG. | Loo, S; Roberts, AW; Anstee, NS; Kennedy, GA; He, SZ-X; Schwarer, AP; Enjeti, AK; D'Rozario, J; Marlton, P; Bilmon, I; Taper, JM; Cull, G; Tiley, C; Verner, E; Hahn, U; Hiwase, DK; Iland, HJ; Murphy, NE; Ramanathan, S; Reynolds, J; Ong, DM; Tiong, IS; Wall, M; Murray, M; Rawling, T; Leadbetter, J; Rowley, L; Latimer, M; Yuen, SLS; Ting, SB; Fong, CY; Morris, KL; Bajel, A; Seymour, JF; Levis, MJ; Wei, AH |
